Composition for Patch Preparation Comprising Drug, Organic Solvent, Lipophilic Mass Base, and Powder

• US 20150174249A1
• Filed: 06/18/2013
• Published: 06/25/2015
• Est. Priority Date: 06/20/2012
• Status: Active Grant

• Current Assignee: MedRx Co., Ltd.
• Original Assignee: MedRx Co., Ltd.
• Inventors: Hamamoto, Hidetoshi, Yamanaka, Katsuhiro, Tanimoto, Takahiro
• Granted Patent: US 10,543,275 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 38/23 Calcitonins
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/18 Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/7053 obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug.

Claims

1. A composition for a non-aqueous patch preparation comprising a drug, an organic solvent, a lipophilic mass base, and a powder.

2. The composition according to claim 1, wherein the powder is insoluble both in the drug solution in the organic solvent and in the lipophilic mass base.

3. The composition according to claim 1, wherein the powder is at least one selected from the group consisting of crystalline cellulose, anhydrous silicic acid, starch, carmellose, carmellose metal salt, kaolin, agar, carrageenan, pectin, powdered sugar, polyethylene powder, and polystyrene sulfonate.

4. The composition according to claim 1, wherein the powder is crystalline cellulose.

5. The composition according to claim 1, wherein the organic solvent comprises an ionic liquid.

6. The composition according to claim 5, wherein the ionic liquid is an alkanolamine organic carboxylate.

7. The composition according to claim 6, wherein said organic carboxylic acid is a combination of a higher fatty acid and an organic carboxylic acid having 3 to 7 carbon atoms.

8. The composition according to claim 7, wherein said higher fatty acid is a saturated or unsaturated fatty acid having 10 to 22 carbon atoms.

9. The composition according to claim 8, wherein said saturated or unsaturated fatty acid having 10 to 22 carbon atoms is at least one selected from the group consisting of decanoic acid, oleic acid, isostearic acid, and myristic acid.

10. The composition according to claim 7, wherein said organic carboxylic acid having 3 to 7 carbon atoms is a carboxylic acid compound having a hydroxyl group and ketone group.

11. The composition according to claim 10, wherein said carboxylic acid compound having a hydroxyl group and a ketone group is at least one selected from the group consisting of lactic acid, levulinic acid, and salicylic acid.

12. The composition according to claim 6, wherein said alkanolamine is at least one selected from the group consisting of triethanolamine, triisopropanolamine, and diisopropanolamine.

13. The composition according to claim 5, wherein said ionic liquid is at least one selected from the group consisting of triethanolamine lactate, triisopropanolamine lactate, triethanolamine levulinate, diisopropanolamine levulinate, triisopropanolamine decanoate, triethanolamine salicylate, diisopropanolamine oleate, triethanolamine isostearate, diisopropanolamine isostearate, and diisopropanolamine myristate.

14. The composition according to claim 7, wherein said ionic liquid of an alkanolamine salt of organic carboxylic acid having 3 to 7 carbon atoms is at least one selected from the group consisting of triethanolamine lactate, triisopropanolamine lactate, triethanolamine levulinate, diisopropanolamine levulinate, triethanolamine salicylate, and triisopropanolamine salicylate.

15. The composition according to claim 8, wherein said ionic liquid of an alkanolamine salt of saturated or unsaturated fatty acid having 10 to 22 carbon atoms is at least one selected from the group consisting of triisopropanolamine decanoate, triethanolamine decanoate, diisopropanolamine decanoate, diisopropanolamine oleate, triethanolamine isostearate, diisopropanolamine isostearate, and diisopropanolamine myristate.

16. The composition according to claim 1, wherein the elastomer of said lipophilic mass base is styrene-isoprene-styrene block copolymer.

17. The composition according to claim 1, wherein said drug is selected from a small molecular medicinal compound, a protein medicine, an antigen peptide, or a nucleic acid derivative.